^
Association details:
| Biomarker: | BCR-ABL1 E255K |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | S81694 (TTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)
Published date:
11/06/2019
Excerpt:
S81694 induced significant apoptosis (70%) in the imatinib resistant BV173 cell line bearing the E255K-BCR-ABL1 mutation.
DOI:
https://doi.org/10.1182/blood-2019-125641
